drugset / Trial / NCT02013765
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.
Timeline
- Start
- 2001-01
- Primary completion
- 2010-01
- Completion
- 2010-01
Outcome
Outcome not reported
Stopped (Enrollment): “Trial was terminated prematurely because of recruitment difficulties.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |